Elevated CD169 expressing monocyte/macrophage promotes systemic inflammation and disease progression in cirrhosis

Lichen Xu1, Chunhong Huang2, Xiaoping Zheng3

  • 1Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.

PubMed

Insights

CD169-positive monocytes are elevated in cirrhosis, driving inflammation and impacting disease progression. Targeting these cells may offer a new therapeutic strategy for advanced liver disease.

Area of Science:

  • Immunology
  • Hepatology
  • Cell Biology

Background:

  • Systemic inflammation is a key factor in advanced cirrhosis progression and prognosis.
  • The specific mechanisms initiating inflammation in cirrhosis remain unclear.
  • The role of CD169-positive (CD169+) monocytes/macrophages in cirrhotic inflammation is unknown.

Purpose of the Study:

  • To investigate the role and function of CD169+ monocytes/macrophages in systemic inflammation associated with advanced cirrhosis.
  • To determine if CD169 expression on monocytes correlates with disease severity and inflammatory markers.
  • To explore the therapeutic potential of targeting CD169+ monocytes/macrophages in cirrhosis.

Main Methods:

  • Flow cytometry was used to analyze CD169+ monocyte percentage, phenotype, and pro-inflammatory function in patient tissues and blood.
  • Transcriptome analysis compared CD169+ and CD169- monocytes.
  • A mouse model with CD169+ monocyte/macrophage depletion was employed to assess their role in liver injury and fibrosis.

Main Results:

  • Cirrhotic patients exhibited increased CD169 expression on monocytes, correlating with inflammatory cytokine levels and disease progression.
  • CD169+ monocytes displayed both M1- and M2-like markers, indicating an immune-activated profile.
  • CD169+ monocytes were found to inhibit neutrophil apoptosis, and their depletion reduced liver inflammation and necrosis but impaired fibrin resolution.

Conclusions:

  • CD169 identifies a subset of monocytes associated with inflammation and disease development in cirrhosis.
  • CD169+ monocytes play a significant role in regulating inflammation and tissue repair in liver injury.
  • Targeting CD169+ monocytes presents a potential therapeutic avenue for managing inflammation and improving survival in cirrhosis.